Biogen blames ‘misinformation’ for cloud over its Alzheimer’s drug

Drugmaker’s defence comes as approval of controversial treatment has come under intense scrutiny

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts

Related Posts